IPWatchdog.com is in the process of transitioning to a newer version of our website. Please be patient with us while we work out all the kinks.

Susie Cheng, Ph.D Image

Susie Cheng, Ph.D

is a Partner and the Chair of Leason Ellis’ China Practice Group. She is also a member of the biotech/pharma group at the firm. She focuses on all aspects of U.S. and global strategic patent protection, licensing of inventions and monetization of intellectual property. Her services include due diligence investigation of patent portfolios, products and involvement in legal proceedings for investment, licensing and acquisition opportunities.

For more information or to contact Susie, please visit her Firm Profile Page.

Recent Articles by Susie Cheng, Ph.D

China’s NMPA and CNIPA Propose Draft Measures on Patent Linkage for Public Comment: Implications for the Future of Innovative and Generic Drugs

The National Medical Products Administration (NMPA), in conjunction with the China National Intellectual Property Administration (CNIPA), recently solicited public comments on the draft of “Measures For the Implementation of Early Resolution Mechanisms for Drug Patent Disputes (Trial)” (“Draft Measures”). The purpose of the Draft Measures is to establish an early resolution mechanism for drug patent disputes. The deadline for submission of comments is October 25, 2020.